Data from Genentech Inc.’s Phase III IMpower150 trial of Tecentriq atezolizumab in first-line non-small cell lung cancer provides the company with its first hard data showing what work lies ahead before it will be ready...

Promising early data for a rare disease lentiviral gene therapy from Orchard Therapeutics Ltd. helped the Orphan disease company raise a $110 million series B round that it thinks will be enough to carry its...

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...

FDA’s regenerative medicines framework could level the global regulatory playing field for products like cell and gene therapies. It describes approaches to implementing expedited development and review pathways that make them comparable, and in some...

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...

The Harvard Business School’s Kraft Precision Medicine Accelerator is tackling a series of initiatives that will position patients to help drive improvements in both clinical care and clinical research.
The accelerator was founded in 2015 with...

Strong early returns from LSP’s first fund explicitly targeting companies that generate savings for healthcare systems had LPs clamoring to get into a second fund that will follow the same strategy.
On Dec. 11, LSP...